Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

Atrogi AB United Kingdom United States of America Sweden California

Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective ?2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential in obesity, diabetes, and age-related muscle lossATR-258 is set to enter Phase 2 trials to confirm its ability to deliver exercise-like benefits, including fat loss, improved muscle strength, and better metabolic control, alone or in combination with GLP-1 therapiesand on LinkedIn.

View original content:https://www.prnewswire.co.uk/news-releases/atrogi-announces-cell-paper-highlighting-transformative-potential-of-muscle-targeted-therapy-in-metabolic-disease-302488159.html